Posted by Michael Wonder on 10 Sep 2019
ProQR receives fast track designation from FDA for QR-1123 for autosomal dominant retinitis pigmentosa
9 September 2019 - ProQR Therapeutics today announced that it received fast track designation from the FDA for QR-1123.
QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin gene.
